logo
logo

C2N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic

May 14, 2020•about 5 years ago

Amount Raised

$20 Million

Description

C2N Diagnostics announced today that it has received a $20 million Program-Related Investment from GHR Foundation, an independent global philanthropy. The funds will position C2N’s Alzheimer’s blood test for entry into the clinic. The investment provides resources to build out C2N’s clinical laboratory testing facility in St. Louis, Missouri and to establish a premium quality, patient testing service

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People